Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease

To date, the development of disease-modifying therapies for Alzheimer’s disease (AD) has largely focused on the removal of amyloid beta Aβ fragments from the CNS. Proteomic profiling of patient fluids may help identify novel therapeutic targets and biomarkers associated with AD pathology. Here, we a...

Descripción completa

Detalles Bibliográficos
Autores principales: Whelan, Christopher D., Mattsson, Niklas, Nagle, Michael W., Vijayaraghavan, Swetha, Hyde, Craig, Janelidze, Shorena, Stomrud, Erik, Lee, Julie, Fitz, Lori, Samad, Tarek A., Ramaswamy, Gayathri, Margolin, Richard A., Malarstig, Anders, Hansson, Oskar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836495/
https://www.ncbi.nlm.nih.gov/pubmed/31694701
http://dx.doi.org/10.1186/s40478-019-0795-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836495/
https://www.ncbi.nlm.nih.gov/pubmed/31694701
http://dx.doi.org/10.1186/s40478-019-0795-2

Ejemplares similares